# A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)

> **NCT00152191** · PHASE3 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 1300 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** UFT (uracil, tegafur)
- **DRUG:** cyclophosphamide, methotrexate, and fluorouracil

## Key facts

- **NCT ID:** NCT00152191
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-10
- **Primary completion:** 2007-10
- **Final completion:** 2008-01
- **Target enrollment:** 1300 (ESTIMATED)
- **Last updated:** 2011-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152191, "A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00152191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*